ADMA Biologics, Inc. Company Review & Valuation

Latest Price
Market Capitalization

About ADMA Biologics, Inc.

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases.

Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

The company also operates source plasma collection facilities in Norcross and Marietta, Georgia.

In Addition, the company offers Nabi-HB for the treatment of acute exposure; and Bivigam for the treatment of primary humoral immunodeficiency.

It distributes its products through independent distributors, sales agents, specialty pharmacies, and others.

The ADMA Biologics, Inc.

was founded in 2004 and is headquartered in Ramsey, New Jersey.

HQ Location
Ramsey, New Jersey

Stock Price

Price data not available for ADMA Biologics, Inc..


Please login or create a free account to view the contents of this section.

Financial Reports

Please login or create a free account to view the contents of this section.

Similar Companies

back to top

Valuu provides insights and tools for self-directed stock investors. It enables you to easily find, valuate and track your stock investments with the help of reliable financial data and transparent analysis tools.

Disclaimer: This website is a data portal, which aggregates information about public companies. It is not a stock broker and does not give advice concerning specific investment decisions or tax or legal advice. All data is provided "as-is" with no guarantee for correctness and/or completeness. All company names, logos, and brands are intellectual property of their respective owners. The use of them is for editorial purposes only and does not imply any affiliation or endorsement.
© 2019-2022 Valuu Analytics Sàrl